Background: Roxadustat (FG-4592) is an oral hypoxia-inducible factor prolyl-hydroxylase inhibitor that promotes erythropoiesis through increasing endogenous erythropoietin, improving iron regulation, and reducing hepcidin.
(NHCT), the Correction of Hemoglobin and Outcomes in Renal Insufficiency (CHOIR) study, the Cardiovascular Risk Reduction by Early Anemia Treatment With Epoetin Beta (CREATE) study, and the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT), [2] [3] [4] [5] which targeted hemoglobin (Hb) values . 11 g/dL, prompted regulatory authorities to institute warnings to use the lowest ESA dose adequate for reducing the need for red blood cell transfusion. The warning also states that no trial has identified an Hb target level, ESA dose, or dosing strategy that does not increase these risks. 6 Similar recommendations have also been made based on observational studies. 7 Post hoc analyses of the mentioned trials point to high ESA doses as the mediator of cardiovascular risk while consistently supporting an inverse relationship between achieved Hb levels and risk. 8 These restrictions on ESAs have subsequently been associated with a decline in Hb levels and an increase in transfusions in patients with ESRD in the United States. 9 Hepcidin has been recently identified as the master regulator of iron metabolism, 10, 11 and levels are elevated in patients with ESRD 12 and those with inflammation. Hepcidin reduces duodenal iron absorption and export of tissue-stored iron-impairing responsiveness to erythropoietin (EPO). Anemia in patients with ESRD is not simply an "EPO-deficiency state," but one of EPO dysregulation coupled with major abnormalities in iron metabolism leading to the need for intravenous (IV) iron. 13 Recent studies demonstrate a role for hypoxia-inducible factor (HIF) in the regulation of endogenous EPO production, the iron transport system, 14 and hepcidin. A new class of drugs, HIF2prolyl hydroxylase inhibitors (HIFPHIs), taking advantage of natural physiology in coordinated erythropoiesis, is being evaluated for the treatment of anemia in chronic kidney disease. 15 Roxadustat (FG-4592) is an orally bioavailable HIF-PHI with a half-life of around 12 hours; thriceweekly administration leads to intermittent activation of genes associated with erythropoiesis, notably including well-characterized HIF targets such as EPO and proteins promoting iron absorption, iron transport, and heme synthesis. [16] [17] [18] In an earlier placebocontrolled 4-week phase 2a study, roxadustat increased Hb levels in non-dialysis-dependent patients with chronic kidney disease in a dosedependent manner and improved iron homeostasis, limiting transient endogenous EPO levels to within or near physiologic range. 19 In ESA-naive incident hemodialysis and peritoneal dialysis patients, roxadustat treatment resulted in a maximum Hb level increase of 13.1 6 0.2 (standard error [SE] of the mean) g/dL over 12 weeks despite a lack of iron repletion requirement at baseline, with Hb values of hemodialysis patients receiving oral iron responding as well as those on IV iron therapy. 20 We present a phase 2 study of patients with ESRD on maintenance hemodialysis therapy whose Hb levels had been previously maintained by epoetin alfa, randomly assigned to roxadustat or to continue epoetin alfa to demonstrate roxadustat's efficacy in maintaining Hb levels when converting from an ESA and to establish the optimum starting dose and dose adjustment regimen to maintain target Hb values.
METHODS

Study Design
This was a randomized, multicenter, open-label, consecutivecohort, multidose study with active comparator IV epoetin alfa in patients with ESRD treated by maintenance hemodialysis in the United States whose Hb levels were previously maintained with IV epoetin alfa (dosage, 75-450 U/kg/wk) and IV iron in the 4 weeks preceding screening. The study, conducted between May 17, 2010, and October 15, 2012, consisted of a screening period of up to 4 weeks, a treatment period of 6 (part 1) or 19 (part 2) weeks, and an 8-(part 1) or 4-week (part 2) follow-up period.
The study was approved by Aspire Institutional Review Board, La Mesa, CA. Participants provided written informed consent.
Participants and Treatment
Eligible patients were aged 18 to 75 years and receiving maintenance hemodialysis thrice weekly for 4 or more months. Hb levels were 9.0 to 13.5 g/dL for 8 weeks, and patients had stable epoetin alfa dosages # 450 U/kg/wk for 4 weeks prior to randomization. A comprehensive list of eligibility criteria is provided (Item S1).
The study design is illustrated in Fig 1 . Part 1 consisted of 3.5 consecutive 6-week dose cohorts in which participants were randomly assigned up to n 5 16 per cohort, 3:1 (roxadustat to epoetin alfa), with oral roxadustat doses fixed at 1.0, 1.5, 1.8, or 2.0 mg/kg thrice weekly. Results of part 1 were used to refine optimal roxadustat starting doses for part 2 (19-week treatment), consisting of 6 consecutive-dose cohorts in which participants were converted to roxadustat from epoetin alfa treatment (Table 1) . Part 2 comprised 90 patients randomly assigned to 6.5 cohorts of roxadustat (n 5 67, with various starting doses) or to continue on epoetin alfa therapy (n 5 23).
Treatment with androgens was prohibited; IV iron use and red blood cell transfusions were guided by rescue criteria (Item S2). Oral iron supplementation was permitted but not required. During the post-treatment follow-up period, roxadustat-treated patients switched back to epoetin alfa.
Dose Modifications
Hb was measured weekly; investigators titrated the roxadustat dose after the initial fixed dosing period based on cohort-specific rules every 4 weeks ( Table 2) . If Hb level increased by .2.0 g/ dL in any 2 weeks, the dose was reduced 1 dose step. For participants randomly assigned to epoetin alfa, dose adjustments were made based on the local standard of care.
Assessments
The primary end point in part 1 (6-week cohorts) was the proportion of participants whose Hb levels did not decrease by .0.5 g/dL from baseline (defined as the mean of the last 3 Hb values obtained prior to the first dose of study treatment). The primary end point in part 2 (19-week cohorts) was the proportion of participants whose mean Hb level was $11 g/dL averaged over the last 4 weeks (weeks 16 through 19). Exploratory analysis included hepcidin levels, correlates of erythropoiesis and iron use (reticulocyte Hb content, soluble transferrin receptor, transferrin, total iron-binding capacity, transferrin saturation, and ferritin), and total serum cholesterol level.
Safety was assessed by physical examinations, clinical laboratory tests, and the incidence and severity of adverse events (AEs) recorded from treatment onset through follow-up.
Evaluation of plasma endogenous EPO levels was conducted at selected sites to compare circulating endogenous EPO levels 0 to 48 hours following roxadustat treatment with EPO levels following exogenous administration of epoetin alfa dosed within the same participants prior to randomization.
Statistical Analysis
The study was not formally powered for noninferiority; the total number of patients and cohort size were considered adequate for phase 2 studies to advise medical decision making and assess relative efficacy. All analyses were exploratory. All participants receiving any dose of study treatment were included in the safety population and safety analyses. Amendment 2 increased the number of cohorts from 4 to 10, extended treatment duration from 6 to 19 weeks for the 5 remaining participants in cohort A-4 and all participants in the new cohorts, and reduced the follow-up period from 8 to 4 weeks. c Amendment 3 allowed dose adjustments to be made after 4 weeks rather than 6 weeks, allowed more rapid dose escalation, and modified some dose adjustment rules. It also added cohorts A-11 and A-12, which were not filled eventually. The efficacy-evaluable population in both part 1 (6-week study) and part 2 (19-week study) included eligible participants who received treatment for 4 or more weeks with corresponding Hb measurements that had not resulted from any rescue therapies (IV iron or red blood cell transfusion) or inadvertent use of ESAs. The efficacy-evaluable population also included all participants who permanently discontinued study medication during the dosing period due to lack of efficacy. A post hoc intention-to-treat analysis was also performed on the primary end point for participants in parts 1 and 2.
The safety and efficacy analyses presented here were based on pooled roxadustat-treated participants across the various dose cohorts and compared with pooled IV epoetin-alfa participants. Mixed model of repeated measurements and/or analysis of covariance/nonparametric models were used for continuous end points, and c 2 or Fisher exact tests, for categorical end points. All alternative hypotheses and statistical comparisons were 2 sided (a 5 0.05). No adjustments for multiplicity were made due to the exploratory nature of the analysis. All null hypotheses were no treatment difference unless specified otherwise. Results are presented as mean 6 standard deviation (SD) or mean 6 standard error of the mean.
The effect of inflammation on dose needs was examined by correlating (linear regression) maintenance dose requirements of epoetin alfa or roxadustat to C-reactive protein (CRP) level, a surrogate for inflammatory state, at baseline (average of last 3 pre2first-dose values) or last 7 of 19 weeks' averages (maintenance phase), respectively, in all efficacy-evaluable participants randomly assigned to 19 weeks of roxadustat treatment and dosed beyond 12 weeks, with valid pre-enrollment epoetin alfa dose data and valid baseline and maintenance phase CRP data (n 5 49).
All safety data were tabulated using descriptive statistics.
RESULTS
Participant Disposition and Characteristics
A total of 144 participants with baseline stable epoetin alfa doses were randomly assigned (3:1) to roxadustat or epoetin alfa; all were dosed and constituted the safety population. Part 1 comprised 54 participants treated for 6 weeks (41 roxadustat and 13 epoetin alfa); part 2 comprised 90 participants treated for 19 weeks (67 roxadustat and 23 epoetin alfa). Reasons for discontinuation from the study were lack of efficacy (n 5 10), withdrawal of consent (n 5 4), AE/serious AE (SAE; n 5 6; including 3 deaths), 3 protocol violations, and 3 others (leaving center, prolonged hospitalization, and kidney transplantation).
There were 125 participants who were efficacyevaluable (flow diagram available as Fig S1) . In general, demographics and baseline characteristics for the randomization arms were statistically similar (Table 3 ). Mean baseline Hb levels for treatment arms ranged from 11.2 to 11.5 g/dL.
Efficacy During 6 Weeks of Treatment
In part 1, a total of 41 participants were randomly assigned to 1 of 4 roxadustat dose cohorts (1.0, 1.5, 1.8 [this cohort was only partly filled], and 2.0 mg/kg thrice weekly), and 13 participants, to the epoetin alfa control arm. The primary end point was Hb level of 20.5 g/dL or greater from baseline by the end of 6 weeks. Roxadustat had a dose-response effect on Hb levels (Fig 2A) . The cohort with the lowest roxadustat dose (1.0 mg/kg) was comparable to epoetin alfa with an Hb level responder rate of 44% as compared to 33%, respectively. Roxadustat doses $ 1.5 mg/kg maintained a higher responder rate than epoetin alfa, with a pooled responder rate of 79% (P 5 0.03; Fig 2A) . Intention-to-treat analysis showed similar results: 63% of all roxadustat participants versus 31% of epoetin alfa participants (P 5 0.06).
Overall, mean change from baseline in Hb level (DHb) after 6 weeks was an increase of 0.3 g/dL in roxadustat-treated participants versus a decrease of 1.0 g/dL in the epoetin alfa group. Mean DHb values were significantly greater for 1.5 mg/kg thrice weekly (10.9 g/dL; P 5 0.03) and 2.0 mg/kg of roxadustat thrice weekly (10.7 g/dL; P 5 0.04) than in the epoetin alfa group. Five of 41 (12%) roxadustat-treated and 2 of 13 (15%) epoetin alfa-treated participants received IV iron for rescue during the treatment phase.
Efficacy During 19 Weeks of Treatment
In part 2, a total of 67 participants were randomly assigned to the remainder of Cohort A-4 (1.8 mg/kg) and 6 additional roxadustat cohorts (Table 1) , and 23 participants were randomly assigned to continue epoetin alfa treatment. For roxadustat overall, 31 of 61 (51%) efficacy-evaluable participants achieved , and 400 mg. Generally, dose was reduced 1 step at a time, but may have been reduced by 2 dose steps as needed. The maximum dose was set at 3.0 mg/kg, but could be increased to 3.5 mg/kg with approval from sponsor. If Hb level has increased by .1.5 g/dL from the baseline Hb value during the first 21 days of dosing, dose was reduced by 1 step (eg, reduction from 100 to 70 mg). If Hb level increased by .2.0 g/dL during any 2-week period, dose was reduced by 1 dose step. Presented as N and % of total with available data followed by presentation of the total number of patients for whom data was available.
Hb level maintenance was 1.68 6 0.65 (SD; range, 0.58-3.39) mg/kg thrice weekly, with starting doses being weight based or tiered weight based (Table S1 ). There were no significant differences in weekly doses over time among dose cohorts except for one cohort in which baseline epoetin alfa doses were 2-fold higher than the other cohorts. Two of 67 (3%) roxadustattreated and 3 of 23 (13%) epoetin alfa-treated participants received IV iron for rescue (P 5 0.1).
Efficacy in Participants With Versus Without Inflammation
We compared roxadustat versus epoetin alfa maintenance dose requirements in all participants randomly assigned to 19 weeks of roxadustat treatment and dosed beyond 12 weeks (maintenance phase) with valid pre-enrollment epoetin alfa dose data and valid baseline and maintenance phase CRP data (see Methods). As documented by others, 21 inflammation as reflected by baseline serum CRP levels was associated with increased pre-enrollment epoetin alfa maintenance dose requirements in these participants (Fig 3A; P 5 0.02). However, in the same participants with Hb levels maintained with roxadustat beyond 12 weeks, average weekly roxadustat maintenance dose requirements during the last 7 weeks of therapy were not associated with CRP levels obtained concurrently (Fig 3B; P 5 0.7) .
Exploratory Measures
In a subgroup of 6 participants, EPO was measured prerandomization following IV epoetin alfa injection and then compared with endogenous EPO levels during treatment with roxadustat ( Fig 4A) . Mean peak EPO levels in participants receiving epoetin alfa (median dose, 90 U/kg/wk) were w700 mIU/mL compared to a peak of levels of w130 mIU/mL at 12 hours in participants receiving a mean roxadustat dose of 1.3 mg/kg.
A progressive decrease in hepcidin levels was observed in participants treated at higher doses of roxadustat for 6 weeks (part 1: Fig 4B; Table 4 ), compared to epoetin alfa. Reduction of hepcidin levels was noted at the end of the 19-week treatment; overall mean change from baseline in roxadustattreated participants was 260.4 6 187.8 (SD) ng/mL (n 5 46) versus 135.6 6 123.4 ng/mL (n 5 18) in the epoetin alfa-treated pool (P 5 0.04). Reticulocyte Hb content was maintained at statistically higher than baseline levels through most of the roxadustat treatment duration, whereas this phenomenon was transient for 3 weeks only with epoetin alfa (Fig 4C) . Transferrin saturation and serum iron levels were not different in the treatment groups.
Total cholesterol levels (nonfasting) were reduced during roxadustat treatment but were without significant change in participants continuing epoetin alfa treatment (Fig 4D) . Figure 3 . Baseline C-reactive protein (CRP) levels are correlated with (A) pre-enrollment epoetin alfa but not (B) roxadustat maintenance dose requirements. *N 5 49: all participants randomly assigned to 19 weeks of roxadustat treatment and dosed beyond 12 weeks (maintenance phase) with valid baseline epoetin alfa dose data and valid baseline and average last 7 of 19 weeks of CRP data. Thus, this analysis did not include the 9 patients discontinued from roxadustat treatment for lack of efficacy (see Fig S1) . Baseline CRP level was the average of the last 3 values prior to the first dose of study drug. CRP is plotted on the x-axis using a logarithmic scale. Abbreviation: LR, linear regression.
participants had at least 1 AE. Thirty-two of 144 (22.2%) participants in the safety population had a total of 50 treatment-emergent SAEs (Table 5) . Of roxadustat-treated participants, 26 of 108 (24.1%) had at least 1 SAE. The only SAE considered as possibly related to roxadustat treatment was acute pancreatitis, diagnosed 2 days after the patient completed 43 days of treatment. Both the sponsor and the independent data monitoring committee considered it unrelated because of a potential alternative cause (detailed under Table 5 ) and the patient had a recurrent episode 28 months after the last dose of study medication. Of epoetin alfa-treated participants, 6 of 36 (17%) had at least 1 SAE.
Exploratory safety analysis of a composite safety event consisting of death, myocardial infarction, stroke, heart failure requiring hospitalization, unstable angina requiring hospitalization, or thromboembolism in the 19-week participants defined post hoc showed a numerically lower rate in roxadustat-treated as compared with epoetin alfa-treated participants. Among participants in the roxadustat group, 8 of 66 (12%) as compared to 4 of 23 (17%) receiving epoetin alfa had a composite safety event. Three roxadustat-treated participants died during the study: a 68-year-old man with known heart failure and coronary and peripheral arterial disease had an unwitnessed death, a 77-year-old man with methicillin-resistant Staphylococcus aureus sepsis, and a 58-year-old man with preexisting allergy to dialysis and cardiovascular disease (acute myocardial infarction, stent, and transient ischemic attacks) prior to enrollment who presented volume overloaded with respiratory failure in whom dialysis was delayed, leading to cardiac arrest. All 3 had significant preexisting cardiovascular risks. None of the deaths was considered related to roxadustat.
DISCUSSION
This phase 2 trial is the first roxadustat study in patients with ESRD on stable hemodialysis therapy whose Hb levels were maintained with epoetin alfa and suggests that roxadustat can maintain Hb levels Kruskal-Wallis test, comparing roxadustat change from baseline with epoetin alfa change from baseline.
for periods up to 19 weeks. Because of prerandomization IV iron use, we realize that differences in iron metabolic values or trends could be masked following the exclusion of IV iron for up to 19 weeks in both groups.
The 6-week dose range portion of this conversion study in hemodialysis patients revealed a dosedependent Hb level response to roxadustat. The Hb effect of a 1.0-mg/kg dose of roxadustat was comparable to, while doses $ 1.5 mg/kg were more effective than epoetin alfa, with a pooled Hb level response at 6 weeks of 79% versus 33%, respectively. In subsequent clinical development, starting doses $ 1.5 mg/kg will need to take into account initial Hb level response during the period of fixed dose and the number of dose adjustments required after 4 weeks. The roxadustat dose for Hb level maintenance ranged from 0.5 to 3.4 (mean dose, w1.7) mg/kg thrice weekly. The effect of roxadustat on Hb level maintenance was durable over the 19-week treatment period of this study. The overall least-squares-mean DHb during study weeks 16 to 19 of roxadustattreated patients was comparable to that in the epoetin alfa arm. Based on these results and historical ESA phase 3 studies, 22 roxadustat appears to be effective and comparable to epoetin alfa in maintaining Hb levels in patients with ESRD receiving hemodialysis. In individuals with higher baseline epoetin alfa dose requirements (eg, cohort A-5), a somewhat higher roxadustat dose requirement was noted, whereas the range of roxadustat dose requirements was not as large as observed for epoetin alfa. A longer study is needed to determine the durability of response in such patients and titration/dose needs.
An important difference between roxadustat and epoetin alfa is the relationship of dose to the inflammatory parameter CRP. Inflammation increases an ESRD patient's dose requirements for epoetin alfa, whether during correction or maintenance. 21 Resistance to ESAs appears to be mediated in part by elevated hepcidin levels, 10, 12 which are increased in inflammation, limiting iron availability. Hepcidin impairs both iron absorption from the duodenal enterocyte and iron release from macrophages, where most iron is stored. This impairment of iron metabolism explains why IV iron produces very high ferritin levels, reflecting preferential accumulation in macrophages. Egress is impaired because hepcidin inactivates ferroportin, the sole iron-exporting process in mammalian cells. This impairment in iron export is an important mechanism leading to the increase in epoetin alfa requirements during inflammation, in effect producing functional iron deficiency and accounting for the linear correlation of epoetin alfa doses with baseline serum CRP levels in the epoetin alfa group. By contrast, roxadustat maintenance dose requirements were independent of baseline CRP levels. This independence of response from CRP levels suggests the potential for roxadustat to overcome the therapeutic barrier to erythropoiesis from the inflammatory component present in ESRD.
Furthermore, Hb levels in the epoetin alfa group appeared to decline gradually over time when IV iron supplementation was discontinued despite the increase in epoetin alfa doses to maintain Hb levels.
23-25
The IV iron exclusion permitted assessment of the impact of roxadustat compared to epoetin on hepcidin and iron delivery indexes to the erythron (reticulocyte Hb content, mean corpuscular volume, total ironbinding capacity, and soluble transferrin receptor) in the coordination of erythropoiesis despite marked differences in the relative elevations in plasma EPO levels induced. Despite high mean ferritin levels . 800 ng/mL, larger declines in transferrin saturation, reticulocyte Hb content, and serum iron levels occurred in the epoetin alfa-treated than roxadustattreated participants. This is consistent with roxadustat's expected positive impact on iron availability.
In a subset of 6 participants, plasma EPO levels following an oral dose of roxadustat were compared with those following an IV dose of epoetin alfa prior to randomization. Following IV epoetin alfa, average plasma EPO levels increased more than 30-fold compared with those seen in healthy persons at sea level. 26 These supraphysiologic levels after exogenous epoetin alfa administration occurred even at doses equivalent to the lowest epoetin alfa dose quartile of hemodialysis patients. 27, 28 In contrast, within the same participant, roxadustat treatment provided modest transient postdose endogenous EPO levels, which peaked at about one-sixth of the level observed with exogenous epoetin alfa dosing. The levels observed are similar to those reported in a previous pharmacokinetics trial. 19 Moreover, these lower baseline endogenous EPO levels were effective in maintaining Hb levels during the study and are consistent with the physiologic EPO response in persons under hypoxic conditions 29 or following an acute decrease in Hb level. 30, 31 The postdose plasma EPO levels measured in the active comparator (epoetin alfa) arm may be unique to this specific agent and IV route of administration, and different routes of administration such as subcutaneous or different agents such as continuous erythropoietin receptor activator (CERA) or darbepoetin alfa may result in different pharmacokinetic profiles in this setting.
Roxadustat as compared to epoetin alfa treatment resulted in different plasma EPO levels, with roxadustat exposing patients to modest levels of endogenous EPO within or near physiologic range. In contrast, the peak and area under the curve of plasma EPO concentrations at the mean of the lowest dose quartile of exogenous epoetin alfa led to much higher levels of exposure. 28 Although ESA dose has been implicated as part of the pathway leading to excessive mortality and cardiovascular events when targeting higher Hb levels, particularly in patients with inflammation and hyporesponsive patients, 8, 32 it has not been proved if this is mediated through higher EPO levels. The potential of roxadustat as a novel therapeutic agent alternative to ESAs to safely treat to a higher Hb level without the need for supraphysiologic epoetin alfa doses might be suggested by 2 observations. First, patients who achieve higher Hb levels at lower ESA doses have lower morbidity and better survival. 33 Second, when Hb levels are . 12.5 g/dL, with a mean Hb level of 13.5 g/dL, and are spontaneously maintained by endogenous EPO production, no increased risk was shown in more than 600 dialysis patients. 34 Although this potential cannot be evaluated within the context of this phase 2 trial, it will be further explored in phase 3.
Another important difference is the effect of roxadustat on serum cholesterol levels. The potential cholesterol-lowering effect of roxadustat was independent of statin use and may be mediated in part by the effects of HIF on degradation 3-hydroxy-3-methylglutaryl coenzyme A reductase, a ratelimiting enzyme in cholesterol biosynthesis. 35 Cholesterol reduction has been reported during high altitude exposure itself. 36 Observations from the current study suggest no obvious safety concerns because the AEs and SAEs reported are consistent with the dialysis patient population. The exploratory composite safety event rate in the 19-week participants was numerically lower in roxadustat-treated compared with epoetin alfa-treated participants.
Limitations of this phase 2 study include its relatively short treatment duration and small sample size. As is true for all phase 2 programs, these limitations may have precluded the identification of a greater risk for uncommon events. 37 A much larger sample size with longer treatment duration would be needed to provide adequate power for manifestation of such toxicities and comparison of cardiovascular safety between roxadustat and ESAs.
In summary, roxadustat, an oral HIF-PHI, was shown to maintain Hb levels in maintenance hemodialysis patients with ESRD receiving a wide range of epoetin alfa doses without IV iron in the short term. Roxadustat also reduced hepcidin levels and regulated iron metabolism. Further development in adequate and well-controlled phase 3 studies is in progress (NCT02273726). Note: Values given as number (percentage). For system organ class incidence, SAEs of the same system organ class in the same patient are counted once only.
Abbreviation: SAE, serious adverse event.
a SAE of acute pancreatitis. This SAE occurred in a 40-year-old man with diabetes mellitus, hyperparathyroidism, hypertension, dyslipidemia, kidney stones, gallstones, and status post cholecystectomy who was a smoker (10 years) and also taking lisinopril and hydrocodone bitartrate plus acetaminophen concomitantly. He presented with a 1-week history of abdominal pain 2 days after his last dose of a 43-day course of roxadustat and acute pancreatitis was diagnosed. Lisinopril and hydrocodone bitartrate plus acetaminophen were stopped, and the patient was hospitalized. The episode of pancreatitis resolved in 8 days. Another episode of pancreatitis in this patient was reported 28 months after the last dose of study medication. Although the investigator considered the SAE of acute pancreatitis as possibly related to roxadustat, both the sponsor and the independent data monitoring committee considered it unrelated because of lack of temporal relationship, potential alternative causes, and the recurrence of pancreatitis when off roxadustat therapy for 28 months. All other SAEs were considered by investigators and sponsor to be unrelated to study medication. medical monitoring: LP, GS; supervision or mentorship: KHPY, TBN; contribution of patients to study and analysis: RP, AB, SW, SD, SZ, PN. Each author contributed important intellectual content during manuscript drafting or revision and accepts accountability for the overall work by ensuring that questions pertaining to the accuracy or integrity of any portion of the work are appropriately investigated and resolved. KHPY takes responsibility that this study has been reported honestly, accurately, and transparently; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned and registered have been explained.
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